Press Releases April 28, 2026 08:00 AM

OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET

OptimizeRx schedules Q1 2026 earnings conference call for May 12 to discuss financial results.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
OPRX

OptimizeRx Corp., a healthcare technology company focused on AI-driven tools to connect life sciences brands with healthcare professionals and patients, announced it will hold a conference call on May 12, 2026, to discuss its financial results for the first quarter ended March 31, 2026. The company aims to provide insights into its performance and answer investor questions during the call.

OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET
OPRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • OptimizeRx will report Q1 2026 financial results with a conference call on May 12, 2026.
  • The company utilizes AI-driven platforms such as Dynamic Audience Activation Platform and Micro-Neighborhood Targeting to enhance marketing in healthcare.
  • OptimizeRx partners with major pharmaceutical and life sciences companies to improve patient engagement and outcomes.

WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Tuesday, May 12, 2026, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2026. The financial results will be issued in a press release prior to the call.

OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:

Date: Tuesday, May 12, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Toll Free: 1-877-407-9716International: 1-201-493-6779Conference ID: 13760191Call me™ Link: https://callme.viavid.com/viavid/?callme=true&passcode=13760191&h=true&info=company-email&r=true&B=6Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1760247&tp_key=80ee98d522


Please call the conference telephone number or log on to the web access link five minutes prior to the start time.

A replay of the call will remain available for 12 months via the investors section of the OptimizeRx website at http://www.optimizerx.com/investors.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.

OptimizeRx Contact
Andy D’Silva, Chief Business Officer
[email protected]

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
[email protected]    


Risks

  • Financial results details are not yet disclosed, leading to potential uncertainty around company performance for Q1 2026.
  • Market and investor reaction may depend heavily on the conference call disclosures and future guidance, introducing volatility.
  • Dependence on partnerships with pharmaceutical companies may pose risks if collaborations weaken or healthcare market conditions change.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026